Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.
- Published In:
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 33, 90-6 (2015)
- Authors:
- Li, Congcong, Bo, Liyan, Liu, Qingqing, Jin, Faguang
- Database ID:
- RPEP-02710
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02710APA
Li, Congcong; Bo, Liyan; Liu, Qingqing; Jin, Faguang. (2015). Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 33, 90-6. https://doi.org/10.1016/j.ijid.2014.12.032
MLA
Li, Congcong, et al. "Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.." International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2015. https://doi.org/10.1016/j.ijid.2014.12.032
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha1 based immunomodulatory therapy for sepsis: a..." RPEP-02710. Retrieved from https://rethinkpeptides.com/research/li-2015-thymosin-alpha1-based-immunomodulatory
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.